TY - JOUR
T1 - Circulating microRNAs and Cytokines as Prognostic Biomarkers for Doxorubicin-Induced Cardiac Injury and for Evaluating the Effectiveness of an Exercise Intervention
AU - Jeyabal, Prince
AU - Bhagat, Anchit
AU - Wang, Fei
AU - Roth, Michael
AU - Livingston, J. Andrew
AU - Gilchrist, Susan C.
AU - Banchs, Jose
AU - Hildebrandt, Michelle A.T.
AU - Chandra, Joya
AU - Deswal, Anita
AU - Koutroumpakis, Efstratios
AU - Wang, Jian
AU - Daw, Najat C.
AU - Honey, Theresa A.
AU - Kleinerman, Eugenie S.
N1 - Publisher Copyright:
© 2023 American Association for Cancer Research.
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Purpose: To define a set of biomarkers that can be used to identify patients at high risk of developing late doxorubicin (DOX)induced cardiac morbidity with the goal of focused monitoring and early interventions. Experimental Design: Mice received phosphate buffered saline or DOX 2.5 mg/kg 2x/week for 2 weeks. Blood samples were obtained before and after therapy for quantification of miRNAs (6 and 24 hours), cytokines (24 hours), and troponin (24 hours, 4 and 6 weeks). Cardiac function was evaluated using echocardiography before and 24 hours after therapy. To assess the effectiveness of exercise intervention in preventing DOX-induced cardiotoxicity blood samples were collected from mice treated with DOX or DOX þ exercise. Plasma samples from 13 DOX-treated patients with sarcoma were also evaluated before and 24 hours after therapy. Results: Elevations in plasma miRNA-1, miRNA-499 and IL1a, IL1b, and IL6 were seen in DOX-treated mice with decreased ejection fraction and fractional shortening 24 hours after DOX therapy. Troponin levels were not elevated until 4 weeks after therapy. In mice treated with exercise during DOX, there was no elevation in these biomarkers and no change in cardiac function. Elevations in these biomarkers were seen in 12 of 13 patients with sarcoma treated with DOX. Conclusions: These findings define a potential set of biomarkers to identify and predict patients at risk for developing acute and late cardiovascular diseases with the goal of focused monitoring and early intervention. Further studies are needed to confirm the predictive value of these biomarkers in late cardiotoxicity.
AB - Purpose: To define a set of biomarkers that can be used to identify patients at high risk of developing late doxorubicin (DOX)induced cardiac morbidity with the goal of focused monitoring and early interventions. Experimental Design: Mice received phosphate buffered saline or DOX 2.5 mg/kg 2x/week for 2 weeks. Blood samples were obtained before and after therapy for quantification of miRNAs (6 and 24 hours), cytokines (24 hours), and troponin (24 hours, 4 and 6 weeks). Cardiac function was evaluated using echocardiography before and 24 hours after therapy. To assess the effectiveness of exercise intervention in preventing DOX-induced cardiotoxicity blood samples were collected from mice treated with DOX or DOX þ exercise. Plasma samples from 13 DOX-treated patients with sarcoma were also evaluated before and 24 hours after therapy. Results: Elevations in plasma miRNA-1, miRNA-499 and IL1a, IL1b, and IL6 were seen in DOX-treated mice with decreased ejection fraction and fractional shortening 24 hours after DOX therapy. Troponin levels were not elevated until 4 weeks after therapy. In mice treated with exercise during DOX, there was no elevation in these biomarkers and no change in cardiac function. Elevations in these biomarkers were seen in 12 of 13 patients with sarcoma treated with DOX. Conclusions: These findings define a potential set of biomarkers to identify and predict patients at risk for developing acute and late cardiovascular diseases with the goal of focused monitoring and early intervention. Further studies are needed to confirm the predictive value of these biomarkers in late cardiotoxicity.
UR - http://www.scopus.com/inward/record.url?scp=85175741176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85175741176&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-23-1055
DO - 10.1158/1078-0432.CCR-23-1055
M3 - Article
C2 - 37651264
AN - SCOPUS:85175741176
SN - 1078-0432
VL - 29
SP - 4430
EP - 4440
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 21
ER -